Rhythm Pharmaceuticals, Inc.
RYTM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,414,500 | $2,651,234 | $1,517,755 | $495,011 |
| - Cash | $89,137 | $60,081 | $127,677 | $59,248 |
| + Debt | $256,568 | $1,260 | $1,944 | $2,551 |
| Enterprise Value | $3,581,931 | $2,592,413 | $1,392,022 | $438,314 |
| Revenue | $130,126 | $77,428 | $23,638 | $3,154 |
| % Growth | 68.1% | 227.6% | 649.5% | – |
| Gross Profit | $116,758 | $68,126 | $21,505 | $2,555 |
| % Margin | 89.7% | 88% | 91% | 81% |
| EBITDA | -$238,090 | -$168,464 | -$174,246 | -$68,454 |
| % Margin | -183% | -217.6% | -737.1% | -2,170.4% |
| Net Income | -$260,602 | -$184,678 | -$181,119 | -$69,612 |
| % Margin | -200.3% | -238.5% | -766.2% | -2,207.1% |
| EPS Diluted | -4.34 | -3.2 | -3.51 | -1.37 |
| % Growth | -35.6% | 8.8% | -156.2% | – |
| Operating Cash Flow | -$113,879 | -$136,157 | -$173,428 | -$146,003 |
| Capital Expenditures | $0 | -$47 | -$4,281 | -$5,434 |
| Free Cash Flow | -$113,879 | -$136,204 | -$177,709 | -$151,437 |